-
1
-
-
77957341503
-
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
-
Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324–1334.
-
(2010)
N Engl J Med.
, vol.363
, Issue.14
, pp. 1324-1334
-
-
Yu, A.L.1
Gilman, A.L.2
Ozkaynak, M.F.3
-
2
-
-
84866623753
-
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission
-
Cheung NK, Cheung IY, Kushner BH, et al. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol. 2012;30(26):3264–3270.
-
(2012)
J Clin Oncol
, vol.30
, Issue.26
, pp. 3264-3270
-
-
Cheung, N.K.1
Cheung, I.Y.2
Kushner, B.H.3
-
3
-
-
0033554684
-
Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
-
Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341(16):1165–1173.
-
(1999)
Children's Cancer Group. N Engl J Med
, vol.341
, Issue.16
, pp. 1165-1173
-
-
Matthay, K.K.1
Villablanca, J.G.2
Seeger, R.C.3
-
4
-
-
77953523121
-
Recent advances in neuroblastoma
-
Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202–2211.
-
(2010)
N Engl J Med
, vol.362
, Issue.23
, pp. 2202-2211
-
-
Maris, J.M.1
-
5
-
-
1642535499
-
Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma
-
Kushner BH, Kramer K, Modak S, Cheung NK. Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma. Clin Can Res. 2004;10(1 Pt 1):84–87.
-
(2004)
Clin Can Res
, vol.10
, Issue.1
, pp. 84-87
-
-
Kushner, B.H.1
Kramer, K.2
Modak, S.3
Cheung, N.K.4
-
6
-
-
34247390662
-
Irinotecan plus temozolomide for relapsed or refractory neuroblastoma
-
Kushner BH, Kramer K, Modak S, Cheung NK. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol. 2006;24(33):5271–5276.
-
(2006)
J Clin Oncol
, vol.24
, Issue.33
, pp. 5271-5276
-
-
Kushner, B.H.1
Kramer, K.2
Modak, S.3
Cheung, N.K.4
-
7
-
-
79951975645
-
Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: A Children's Oncology Group study
-
Bagatell R, London WB, Wagner LM, et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: A Children's Oncology Group study. J Clin Oncol. 2011;29(2):208–213.
-
(2011)
J Clin Oncol
, vol.29
, Issue.2
, pp. 208-213
-
-
Bagatell, R.1
London, W.B.2
Wagner, L.M.3
-
8
-
-
0035138511
-
A phase I study of irinotecan in pediatric patients: A pediatric oncology group study
-
Blaney S, Berg SL, Pratt C, et al. A phase I study of irinotecan in pediatric patients: A pediatric oncology group study. Clin Can Res. 2001;7(1):32–37.
-
(2001)
Clin Can Res
, vol.7
, Issue.1
, pp. 32-37
-
-
Blaney, S.1
Berg, S.L.2
Pratt, C.3
-
9
-
-
0142023876
-
A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors
-
Vassal G, Doz F, Frappaz D, et al. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol. 2003;21(20):3844–3852.
-
(2003)
J Clin Oncol
, vol.21
, Issue.20
, pp. 3844-3852
-
-
Vassal, G.1
Doz, F.2
Frappaz, D.3
-
10
-
-
35648981948
-
Phase II trial of irinotecan in children with refractory solid tumors: A Children's Oncology Group Study
-
Bomgaars LR, Bernstein M, Krailo M, et al. Phase II trial of irinotecan in children with refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol. 2007;25(29):4622–4627.
-
(2007)
J Clin Oncol
, vol.25
, Issue.29
, pp. 4622-4627
-
-
Bomgaars, L.R.1
Bernstein, M.2
Krailo, M.3
-
11
-
-
54449087562
-
A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: A European cooperation of the Societe Francaise d'Oncologie Pediatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG)
-
Vassal G, Giammarile F, Brooks M, et al. A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: A European cooperation of the Societe Francaise d'Oncologie Pediatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG). Eur J Cancer. 2008;44(16):2453–2460.
-
(2008)
Eur J Cancer
, vol.44
, Issue.16
, pp. 2453-2460
-
-
Vassal, G.1
Giammarile, F.2
Brooks, M.3
-
12
-
-
13444259339
-
Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma
-
Kushner BH, Kramer K, Modak S, Cheung NK. Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma. Cancer. 2005;103(4):858–862.
-
(2005)
Cancer
, vol.103
, Issue.4
, pp. 858-862
-
-
Kushner, B.H.1
Kramer, K.2
Modak, S.3
Cheung, N.K.4
-
13
-
-
34247337237
-
Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: A joint Societe Francaise des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study
-
Rubie H, Chisholm J, Defachelles AS, et al. Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: A joint Societe Francaise des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study. J Clin Oncol. 2006;24(33):5259–5264.
-
(2006)
J Clin Oncol
, vol.24
, Issue.33
, pp. 5259-5264
-
-
Rubie, H.1
Chisholm, J.2
Defachelles, A.S.3
-
14
-
-
0030698003
-
Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects
-
Pourquier P, Pilon AA, Kohlhagen G, Mazumder A, Sharma A, Pommier Y. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects. J Biol Chem. 1997;272(42):26441–26447.
-
(1997)
J Biol Chem
, vol.272
, Issue.42
, pp. 26441-26447
-
-
Pourquier, P.1
Pilon, A.A.2
Kohlhagen, G.3
Mazumder, A.4
Sharma, A.5
Pommier, Y.6
-
15
-
-
10744231592
-
Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors
-
Wagner LM, Crews KR, Iacono LC, et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Can Res. 2004;10(3):840–848.
-
(2004)
Clin Can Res
, vol.10
, Issue.3
, pp. 840-848
-
-
Wagner, L.M.1
Crews, K.R.2
Iacono, L.C.3
-
16
-
-
0035951364
-
Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma
-
Ribatti D, Surico G, Vacca A, et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma. Life Sci. 2001;68(10):1161–1168.
-
(2001)
Life Sci
, vol.68
, Issue.10
, pp. 1161-1168
-
-
Ribatti, D.1
Surico, G.2
Vacca, A.3
-
17
-
-
34250710180
-
Prominent microvascular proliferation in clinically aggressive neuroblastoma
-
Peddinti R, Zeine R, Luca D, et al. Prominent microvascular proliferation in clinically aggressive neuroblastoma. Clin Can Res. 2007;13(12):3499–3506.
-
(2007)
Clin Can Res
, vol.13
, Issue.12
, pp. 3499-3506
-
-
Peddinti, R.1
Zeine, R.2
Luca, D.3
-
18
-
-
0037699954
-
The biology of VEGF and its receptors
-
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–676.
-
(2003)
Nat Med
, vol.9
, Issue.6
, pp. 669-676
-
-
Ferrara, N.1
Gerber, H.P.2
LeCouter, J.3
-
19
-
-
0035175686
-
Expression of angiogenic factors and tumor progression in human neuroblastoma
-
Komuro H, Kaneko S, Kaneko M, Nakanishi Y. Expression of angiogenic factors and tumor progression in human neuroblastoma. J Cancer Res Clin Oncol. 2001;127(12):739–743.
-
(2001)
J Cancer Res Clin Oncol
, vol.127
, Issue.12
, pp. 739-743
-
-
Komuro, H.1
Kaneko, S.2
Kaneko, M.3
Nakanishi, Y.4
-
20
-
-
68549112845
-
The angiogenic growth factors HGF and VEGF in serum and plasma from neuroblastoma patients
-
Skoldenberg EG, Larsson A, Jakobson A, et al. The angiogenic growth factors HGF and VEGF in serum and plasma from neuroblastoma patients. Anticancer Res. 2009;29(8):3311–3319.
-
(2009)
Anticancer Res
, vol.29
, Issue.8
, pp. 3311-3319
-
-
Skoldenberg, E.G.1
Larsson, A.2
Jakobson, A.3
-
21
-
-
0036185180
-
VEGF upregulates Bcl-2 expression and is associated with decreased apoptosis in neuroblastoma cells
-
Beierle EA, Strande LF, Chen MK. VEGF upregulates Bcl-2 expression and is associated with decreased apoptosis in neuroblastoma cells. J Pediatr Surg. 2002;37(3):467–471.
-
(2002)
J Pediatr Surg
, vol.37
, Issue.3
, pp. 467-471
-
-
Beierle, E.A.1
Strande, L.F.2
Chen, M.K.3
-
22
-
-
0030856731
-
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
-
Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57(20):4593–4599.
-
(1997)
Cancer Res
, vol.57
, Issue.20
, pp. 4593-4599
-
-
Presta, L.G.1
Chen, H.2
O'Connor, S.J.3
-
24
-
-
38649105118
-
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A Children's Oncology Group Study
-
Glade Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol. 2008;26(3):399–405.
-
(2008)
J Clin Oncol
, vol.26
, Issue.3
, pp. 399-405
-
-
Glade Bender, J.L.1
Adamson, P.C.2
Reid, J.M.3
-
25
-
-
83055162488
-
Bevacizumab in pediatric patients: How safe is it?
-
de Pasquale MD, Castellano A, de Sio L, et al. Bevacizumab in pediatric patients: How safe is it? Anticancer Res. 2011;31(11):3953–3957.
-
(2011)
Anticancer Res
, vol.31
, Issue.11
, pp. 3953-3957
-
-
de Pasquale, M.D.1
Castellano, A.2
de Sio, L.3
-
26
-
-
84941348641
-
Safety of bevacizumab in patients younger than 4 years of age
-
Millan NC, Poveda MJ, Cruz O, Mora J. Safety of bevacizumab in patients younger than 4 years of age. Clin Transl Oncol. 2016;18(5):464–468.
-
(2016)
Clin Transl Oncol
, vol.18
, Issue.5
, pp. 464-468
-
-
Millan, N.C.1
Poveda, M.J.2
Cruz, O.3
Mora, J.4
-
27
-
-
84953351685
-
Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation
-
Han K, Peyret T, Quartino A, et al. Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation. Br J Clin Pharmacol. 2016;81(1):148–160.
-
(2016)
Br J Clin Pharmacol
, vol.81
, Issue.1
, pp. 148-160
-
-
Han, K.1
Peyret, T.2
Quartino, A.3
-
28
-
-
34447121919
-
Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy
-
Dickson PV, Hamner JB, Sims TL, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Can Res. 2007;13(13):3942–3950.
-
(2007)
Clin Can Res
, vol.13
, Issue.13
, pp. 3942-3950
-
-
Dickson, P.V.1
Hamner, J.B.2
Sims, T.L.3
-
29
-
-
47549086112
-
Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease
-
Sims TL, Williams RF, Ng CY, Rosati SF, Spence Y, Davidoff AM. Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease. Surgery. 2008;144(2):269–275.
-
(2008)
Surgery
, vol.144
, Issue.2
, pp. 269-275
-
-
Sims, T.L.1
Williams, R.F.2
Ng, C.Y.3
Rosati, S.F.4
Spence, Y.5
Davidoff, A.M.6
-
30
-
-
43549097145
-
Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts
-
Kaneko S, Ishibashi M, Kaneko M. Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts. Cancer Sci. 2008;99(6):1209–1217.
-
(2008)
Cancer Sci
, vol.99
, Issue.6
, pp. 1209-1217
-
-
Kaneko, S.1
Ishibashi, M.2
Kaneko, M.3
-
31
-
-
0027239723
-
Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment
-
Brodeur G, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol. 1993;11:1466–1477.
-
(1993)
J Clin Oncol
, vol.11
, pp. 1466-1477
-
-
Brodeur, G.1
Pritchard, J.2
Berthold, F.3
-
32
-
-
33750483287
-
Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma
-
Messina JA, Cheng SC, Franc BL, et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer. 2006;47(7):865–874.
-
(2006)
Pediatr Blood Cancer
, vol.47
, Issue.7
, pp. 865-874
-
-
Messina, J.A.1
Cheng, S.C.2
Franc, B.L.3
-
33
-
-
81755171117
-
Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study
-
Park JR, Scott JR, Stewart CF, et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study. J Clin Oncol. 2011;29(33):4351–4357.
-
(2011)
J Clin Oncol
, vol.29
, Issue.33
, pp. 4351-4357
-
-
Park, J.R.1
Scott, J.R.2
Stewart, C.F.3
-
34
-
-
84877666198
-
5-Day/5-drug myeloablative outpatient regimen for resistant neuroblastoma
-
Kushner BH, Modak S, Kramer K, Basu EM, Roberts SS, Cheung NK. 5-Day/5-drug myeloablative outpatient regimen for resistant neuroblastoma. Bone Marrow Transplant. 2013;48(5):642–645.
-
(2013)
Bone Marrow Transplant
, vol.48
, Issue.5
, pp. 642-645
-
-
Kushner, B.H.1
Modak, S.2
Kramer, K.3
Basu, E.M.4
Roberts, S.S.5
Cheung, N.K.6
-
35
-
-
84895743330
-
Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A Children's Oncology Group Study
-
Bagatell R, Norris R, Ingle AM, et al. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A Children's Oncology Group Study. Pediatr Blood Cancer. 2014;61(5):833–839.
-
(2014)
Pediatr Blood Cancer
, vol.61
, Issue.5
, pp. 833-839
-
-
Bagatell, R.1
Norris, R.2
Ingle, A.M.3
-
36
-
-
84866734693
-
A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma
-
Furman WL, McGregor LM, McCarville MB, et al. A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma. Invest New Drugs. 2012;30(4):1660–1670.
-
(2012)
Invest New Drugs
, vol.30
, Issue.4
, pp. 1660-1670
-
-
Furman, W.L.1
McGregor, L.M.2
McCarville, M.B.3
-
37
-
-
84963799476
-
Phase I study of the aurora a kinase inhibitor alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) trial
-
DuBois SG, Marachelian A, Fox E, et al. Phase I study of the aurora a kinase inhibitor alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) trial. J Clin Oncol. 2016;34(12):1368–1375.
-
(2016)
J Clin Oncol
, vol.34
, Issue.12
, pp. 1368-1375
-
-
DuBois, S.G.1
Marachelian, A.2
Fox, E.3
-
38
-
-
84860538848
-
Phase I study of vincristine, irinotecan, and (1)(3)(1)I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: A new approaches to neuroblastoma therapy trial
-
DuBois SG, Chesler L, Groshen S, et al. Phase I study of vincristine, irinotecan, and (1)(3)(1)I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: A new approaches to neuroblastoma therapy trial. Clin Can Res. 2012;18(9):2679–2686.
-
(2012)
Clin Can Res
, vol.18
, Issue.9
, pp. 2679-2686
-
-
DuBois, S.G.1
Chesler, L.2
Groshen, S.3
-
39
-
-
84923021432
-
Antiangiogenic therapy for high-grade glioma
-
Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N. Antiangiogenic therapy for high-grade glioma. Cochrane Database Syst Rev. 2014;9:CD008218.
-
(2014)
Cochrane Database Syst Rev
, vol.9
, pp. CD008218
-
-
Khasraw, M.1
Ameratunga, M.S.2
Grant, R.3
Wheeler, H.4
Pavlakis, N.5
-
40
-
-
77954578108
-
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: A Pediatric Brain Tumor Consortium study
-
Gururangan S, Chi SN, Young Poussaint T, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: A Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010;28(18):3069–3075.
-
(2010)
J Clin Oncol
, vol.28
, Issue.18
, pp. 3069-3075
-
-
Gururangan, S.1
Chi, S.N.2
Young Poussaint, T.3
-
41
-
-
84880337248
-
Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors
-
Wagner L, Turpin B, Nagarajan R, Weiss B, Cripe T, Geller J. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors. Pediatr. Blood Cancer. 2013;60(9):1447–1451.
-
(2013)
Pediatr. Blood Cancer
, vol.60
, Issue.9
, pp. 1447-1451
-
-
Wagner, L.1
Turpin, B.2
Nagarajan, R.3
Weiss, B.4
Cripe, T.5
Geller, J.6
-
42
-
-
84893463503
-
Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab
-
Venkatramani R, Malogolowkin MH, Mascarenhas L. Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab. Pediatr. Blood Cancer. 2014;61(4):756–759.
-
(2014)
Pediatr. Blood Cancer
, vol.61
, Issue.4
, pp. 756-759
-
-
Venkatramani, R.1
Malogolowkin, M.H.2
Mascarenhas, L.3
-
43
-
-
84887997111
-
Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): A Pediatric Brain Tumor Consortium Study (PBTC-022)
-
Fangusaro J, Gururangan S, Poussaint TY, et al. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): A Pediatric Brain Tumor Consortium Study (PBTC-022). Cancer. 2013;119(23):4180–4187.
-
(2013)
Cancer
, vol.119
, Issue.23
, pp. 4180-4187
-
-
Fangusaro, J.1
Gururangan, S.2
Poussaint, T.Y.3
|